Pentoxifylline and Lumbar Radiculopathy

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this prospective controlled crossover study is to evaluate the efficacy and safety of pentoxifylline per os (800 mg daily) in the management of lumbar radiculopathy

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St Joseph University, Beirut, Lebanon
• Treatments: Acetaminophen; Ibuprofen; Pentoxifylline; Pregabalin

Criteria

Inclusion Criteria:

• Unilateral lumbar radiculopathy

• Disc hernia confirming the diagnosis with radio-clinical concordance

Exclusion Criteria:

• Radicular deficit needing surgery

• Cauda equine syndrome

• Absence of radio-clinical concordance on MRI

• Contraindication for anti-inflammatory (Hypertension, renal insufficiency, gastric ulcer …)

• Previous intolerance to pentoxifylline, and/or to pregabalin and/or paracetamol

• Pregnancy

• Follow-up not possible

• Hepatic dysfunction

• History of drug abuse

• Current use of tramadol, codeine and/or morphine and its derivative

• Antidepressant use